• 
  Loic Ah-Thiane, Caroline Rousseau, Maud Aumont, Axel Cailleteau, Mélanie Doré, et al.. The Sentinel Lymph Node in Treatment Planning: A Narrative Review of Lymph-Flow-Guided Radiotherapy. Cancers, 2023, 15 (10), pp.2736. ⟨10.3390/cancers15102736⟩. ⟨hal-04755878⟩
• 
  Gunjan Kayal, Nathaly Barbosa, Carlos Calderón Marín, Ludovic Ferrer, José-Alejandro Fragoso-Negrín, et al.. Quality Assurance Considerations in Radiopharmaceutical Therapy Dosimetry Using PLANETDose: An International Atomic Energy Agency Study. Journal of Nuclear Medicine, 2024, 65 (1), pp.125-131. ⟨10.2967/jnumed.122.265340⟩. ⟨hal-04753484⟩
• 
  Marcela Carausu, Matthieu Carton, Luc Cabel, Anne Patsouris, Christelle Levy, et al.. Clinicopathological characteristics and prognosis of breast cancer patients with isolated central nervous system metastases in the multicentre ESME database. Therapeutic Advances in Medical Oncology, 2022, 14, pp.175883592210770. ⟨10.1177/17588359221077082⟩. ⟨hal-03867853⟩
• 
  Fabienne Lesueur, Noura Mebirouk, Yue Jiao, Laure Barjhoux, Muriel Belotti, et al.. GEMO, a National Resource to Study Genetic Modifiers of Breast and Ovarian Cancer Risk in BRCA1 and BRCA2 Pathogenic Variant Carriers. Frontiers in Oncology, 2018, 8, pp.490. ⟨10.3389/fonc.2018.00490⟩. ⟨hal-01926758⟩
• 
  Timothy Rebbeck, Tara Friebel, Eitan Friedman, Ute Hamann, Dezheng Huo, et al.. Mutational spectrum in a worldwide study of 29,700 families with BRCA1 or BRCA2 mutations. Human Mutation, 2018, 39 (5), pp.593-620. ⟨10.1002/humu.23406⟩. ⟨hal-02351570⟩
• 
  Emeline Tabouret, François Bertucci, Jean-Yves Pierga, Thierry Petit, Christelle Levy, et al.. MMP2 and MMP9 serum levels are associated with favorable outcome in patients with inflammatory breast cancer treated with bevacizumab-based neoadjuvant chemotherapy in the BEVERLY-2 study. Oncotarget, 2016, 7 (14), pp.18531-18540. ⟨10.18632/oncotarget.7612⟩. ⟨hal-03623733⟩
• 
  S. Peters, A. Scherpereel, R. Cornelissen, Y. Oulkhouir, L. Greillier, et al.. First-line nivolumab plus ipilimumab versus chemotherapy in patients with unresectable malignant pleural mesothelioma: 3-year outcomes from CheckMate 743. Annals of Oncology, 2022, 33 (5), pp.488-499. ⟨10.1016/j.annonc.2022.01.074⟩. ⟨hal-04085315⟩
• 
  Quentin Dominique Thomas, Amal Boussere, Jean-Marc Classe, Christophe Pomel, Hélène Costaz, et al.. Optimal timing of interval debulking surgery for advanced epithelial ovarian cancer: A retrospective study from the ESME national cohort. Gynecologic Oncology, 2022, 167 (1), pp.11-21. ⟨10.1016/j.ygyno.2022.08.005⟩. ⟨hal-03868125⟩
• 
  Grégoire Marret, Stéphane Temam, Maud Kamal, Caroline Even, Jean-Pierre Delord, et al.. Randomized phase II study of preoperative afatinib in untreated head and neck cancers: predictive and pharmacodynamic biomarkers of activity. Scientific Reports, 2023, 13, pp.22524. ⟨10.1038/s41598-023-49887-4⟩. ⟨hal-04543900⟩
• 
  Thibaud Charrier, Brice Fresneau, Nadia Haddy, Boris Schwartz, Neige Journy, et al.. Increased Cardiac Risk After a Second Malignant Neoplasm Among Childhood Cancer Survivors, a FCCSS Study. RADRES, Oct 2022, Waikoloa, United States. ⟨hal-04488310⟩
• 
  Imène Mansouri, Rodrigue S Allodji, Catherine Hill, Chiraz El‐fayech, François Pein, et al.. The role of irradiated heart and left ventricular volumes in heart failure occurrence after childhood cancer. European Journal of Heart Failure, 2018, 21 (4), pp.509 - 518. ⟨10.1002/ejhf.1376⟩. ⟨inserm-04439245⟩
• 
  Grégory Delpon, Alexandre Escande, Timothée Ruef, Julien Darréon, Jimmy Fontaine, et al.. Comparison of Automated Atlas-Based Segmentation Software for Postoperative Prostate Cancer Radiotherapy. Frontiers in Oncology, 2016, 6, ⟨10.3389/fonc.2016.00178⟩. ⟨hal-01683878⟩
• 
  Catherine M. Phelan, Karoline B. Kuchenbaecker, Jonathan Tyrer, Siddhartha Kar, Kate Lawrenson, et al.. Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer. Nature Genetics, 2017, 49 (5), pp.680-691. ⟨10.1038/ng.3826⟩. ⟨hal-01778538⟩
• 
  Manon de Vries-Brilland, Nathalie Rioux-Leclercq, Maxime Meylan, Jonathan Dauvé, Christophe Passot, et al.. Comprehensive analyses of immune tumor microenvironment in papillary renal cell carcinoma. Journal for Immunotherapy of Cancer, 2023, Journal for ImmunoTherapy of Cancer, 11 (11), pp.e006885. ⟨10.1136/jitc-2023-006885⟩. ⟨hal-04341909⟩
• 
  Jean-Luc Raoul, Marie-Françoise Heymann, Frédéric Dumont, Alain Morel, Hélène Senellart, et al.. Case Report: Grade 2 Metastatic Pancreatic Neuroendocrine Tumor With Progression of One Metastasis After Pregnancy to Grade 3 Large-Cell Neuroendocrine Carcinoma: One Case Cured by Resection With Genomic Characterization of the Two Components. Frontiers in Oncology, 2021, 11, ⟨10.3389/fonc.2021.646992⟩. ⟨hal-03623095⟩
• 
  Clémence Basse, Antoine Italiano, Nicolas Penel, Olivier Mir, Claire Chemin, et al.. Sarcomas in patients over 90: Natural history and treatment—A nationwide study over 6 years. International Journal of Cancer, 2019, 145 (8), pp.2135-2143. ⟨10.1002/ijc.32307⟩. ⟨hal-02504786⟩
• 
  Margot Lavy, Vanessa Gauttier, Alison Dumont, Florian Chocteau, Sophie Deshayes, et al.. ChemR23 activation reprograms macrophages toward a less inflammatory phenotype and dampens carcinoma progression. Frontiers in Immunology, 2023, 14, pp.3606 - 3619. ⟨10.3389/fimmu.2023.1196731⟩. ⟨inserm-04198031⟩
• 
  Stéphane Culine, Aude Fléchon, Gwenaelle Gravis, Guilhem Roubaud, Yohann Loriot, et al.. Dose-Dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin With or Without Panitumumab in Patients With Advanced Urothelial Carcinoma: Multicenter, Randomized, French Unicancer GETUG/AFU 19 Study. Clinical Genitourinary Cancer, 2021, 19 (4), pp.e216-e222. ⟨10.1016/j.clgc.2021.02.005⟩. ⟨hal-03631553⟩
• 
  Victoria Corvest, Perrine Marec-Bérard, Cyril Lervat, Hélène D. Pacquement, Maud Toulmonde, et al.. Late toxicity comparison of alkylating-based maintenance regimen with cyclophosphamide (VAC) vs ifosfamide (VAI) in Ewing sarcoma survivors treated in the randomized clinical trial Euro-EWING99-R1 in France. International Journal of Cancer, 2023, 152 (8), pp.1659-1667. ⟨10.1002/ijc.34326⟩. ⟨hal-04122360⟩
• 
  Renaud Sabatier, Cécile Vicier, Séverine Garnier, Arnaud Guille, Nadine Carbuccia, et al.. Circulating tumor DNA predicts efficacy of a dual AKT/p70S6K inhibitor (LY2780301) plus paclitaxel in metastatic breast cancer: plasma analysis of the TAKTIC phase IB/II study. Molecular Oncology, 2022, 16 (10), pp.2057-2070. ⟨10.1002/1878-0261.13188⟩. ⟨hal-03583253⟩

100

128